2022 American Academy of Dermatology (AAD) Annual Meeting

Baricitinib may improve hair regrowth in alopecia areata

Roshini Claire Anthony, 20220502150001

A once-daily dose of oral baricitinib may encourage hair regrowth in patients with severe alopecia areata, according to results of the phase III BRAVE-AA studies presented at AAD 2022.

Dupilumab stops the itch, clears skin lesions in phase III trial

Elvira Manzano, 20220429000000

The human monoclonal IgG4 antibody dupilumab effectively treats prurigo nodularis (PN), including itching and skin lesions, weeks after treatment in the phase III randomized, double-blind, LIBERTY-PN PRIME2 trial. Hopefully, this brings relief to patients suffering from uncontrolled PN.

Roflumilast cream reduces psoriasis severity

Elaine Soliven, 20220427000000

Using a topical roflumilast cream to treat patients with chronic plaque psoriasis yields a significant improvement in disease severity, achieving a clear or almost clear IGA* status, based on a pooled analysis of the DERMIS-1** and DERMIS-2*** studies presented at AAD 2022.

Cutaneous reactions after 1st COVID-19 vaccine dose no reason to forgo 2nd dose

Elvira Manzano, 20220427000000

Skin reactions to the first COVID-19 vaccine in some individuals shouldn’t be a reason to leave out the second dose, or a scheduled booster if tolerable, according to an analysis presented at AAD 2022.